Website
News25/Ratings10
Latest news
25 items- SECSEC Form S-8 filed by Aadi Bioscience Inc.S-8 - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
- SECAadi Bioscience Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
- SECAadi Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aadi Bioscience, Inc. (0001422142) (Filer)
- SECSEC Form D filed by Aadi Bioscience Inc.D - Aadi Bioscience, Inc. (0001422142) (Filer)
- PRAadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate UpdateMORRISTOWN, N.J., March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. Contact:IR@aadibio.com View original content to download multimedia:https://w
- SECSEC Form SCHEDULE 13G filed by Aadi Bioscience Inc.SCHEDULE 13G - Aadi Bioscience, Inc. (0001422142) (Subject)
- INSIDERDirector Dalal Anupam was granted 1,561,000 shares (SEC Form 4)4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Aadi Bioscience Inc.SCHEDULE 13D/A - Aadi Bioscience, Inc. (0001422142) (Subject)
- INSIDERDirector Castelein Caley was granted 1,666,000 shares (SEC Form 4)4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
- INSIDERDirector Zhao Baiteng was granted 1,250,000 shares (SEC Form 4)4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Dornan David4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
- INSIDEROfficer Ball Bryan converted options into 5,000 shares, sold $5,045 worth of shares (2,147 units at $2.35) and was granted 100,000 shares, increasing direct ownership by 103% to 202,853 units (SEC Form 4)4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
- INSIDERSEC Form 4 filed by Director Aghazadeh Behzad4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
- SECAadi Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure8-K - Aadi Bioscience, Inc. (0001422142) (Filer)
- PRAadi Bioscience Announces Closing of $100 Million PIPE FinancingMORRISTOWN, N.J., March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the closing of its previously announced private placement. The private placement was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han, co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners, for total gross proceeds of approximately $100 million. Aadi sold and issued an aggregate of 21,592
- INSIDERCHIEF FINANCIAL OFFICER Giacobello Scott M. converted options into 6,750 shares and sold $6,594 worth of shares (2,806 units at $2.35), increasing direct ownership by 20% to 23,944 units (SEC Form 4)4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Lennon David James converted options into 16,250 shares and sold $13,372 worth of shares (5,690 units at $2.35), increasing direct ownership by 46% to 33,429 units (SEC Form 4)4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
- PRAadi Bioscience Announces Approval of All Proposals at Special Meeting of StockholdersMORRISTOWN, N.J., March 3, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced that the Company's stockholders have approved all proposals voted on at the Company's Special Meeting of Stockholders ("Special Meeting") held on February 28, 2025. Approved proposals include: Divestiture Proposal. The approval of the sale by Aadi to KAKEN INVESTMENTS INC. ("Kaken") of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. ("Aadi Sub") and thereby all or substantially all of Aadi's assets related to its FYARRO® (si
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Aadi Bioscience Inc.SCHEDULE 13D/A - Aadi Bioscience, Inc. (0001422142) (Subject)
- PRAadi Bioscience to Present at the TD Cowen 45th Annual Healthcare ConferenceMORRISTOWN, N.J., Feb. 24, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) announced today its presentation at the TD Cowen 45th Annual Healthcare Conference, taking place March 3-5, 2025, in Boston, MA. Dave Lennon, PhD, CEO, will present a company overview on Monday, March 3, 2025, from 9:50 – 10:20 AM ET. The presentation will be webcast live on the IR pages of the Aadi Bioscience website and will be available for replay for approximately 30 days following the investor event. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with diffi
- SECSEC Form DEFA14A filed by Aadi Bioscience Inc.DEFA14A - Aadi Bioscience, Inc. (0001422142) (Filer)
- INSIDERSEC Form 3 filed by new insider Dornan David3 - Aadi Bioscience, Inc. (0001422142) (Issuer)
- SECSEC Form DEFA14A filed by Aadi Bioscience Inc.DEFA14A - Aadi Bioscience, Inc. (0001422142) (Filer)
- PRAadi Bioscience Appoints David Dornan, PhD, as Chief Scientific OfficerSeasoned Oncology Leader Brings Extensive ADC Expertise to Support Company's New Pipeline MORRISTOWN, N.J., Feb. 18, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) today announced the appointment of David Dornan, PhD as the Company's Chief Scientific Officer (CSO). Dr. Dornan contributes more than two decades of experience in oncology drug discovery and development, with deep expertise in antibody-drug conjugates (ADCs) and other targeted cancer therapies. "David's extensive experience in ADC development and track record of translating novel oncology discoveries into clinical programs make him an ideal leader as we seek to rapidly advance our newly in-licensed ADC portfolio," said
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aadi Bioscience Inc.SCHEDULE 13G/A - Aadi Bioscience, Inc. (0001422142) (Subject)